Oncologie et hématologie
Passionné par la collaboration pour un remède
Nous vivons dans l’« âge d’or » de la recherche et la découverte sur le cancer. Nos connaissances et notre capacité à avoir un impact direct sur les cellules cancéreuses augmentent à un rythme rapide, et les patients vivent plus longtemps grâce aux progrès de la génétique, de l’immunothérapie et de la médecine de précision.
Cela ne fait qu’alimenter notre sentiment d’urgence pour les nombreux patients qui continuent à perdre leur combat contre le cancer.
Enabling your boldest aspirations with experience, insight and scientific innovation
Our therapeutic expertise in oncology and hematology runs deep and it also runs wide – far beyond the offerings of a traditional contract research organization (CRO). Our service offerings in oncology extend from preclinical and translational science to clinical development, regulatory and commercialization/marketing capabilities.
We listen closely and then leverage the right experience, insights and capabilities across our global organization to offer thoughtful, integrated solutions for achieving your goals.
Diverse and measurable experience across the full range of cancer therapies
Notre équipe de traitements ciblés se concentre exclusivement sur ces nouveaux traitements, y compris ceux basés sur les biomarqueurs, les biosimilaires, les conjugués anticorps-médicaments et d'autres petites molécules.
Our Immuno-Oncology team focuses exclusively on studies of therapies that incite the immune system to combat cancer. Our clinical professionals are currently supporting new approaches to precision medicine in solid tumors, working with cutting-edge therapies including combination immunotherapies and complex study designs (basket studies, platform trials, umbrella trials, etc.) across all phases of clinical development. We are experienced with conducting trials at the forefront of newer immunotherapy discoveries, including studies of novel immunomodulators and combination treatments.
At Syneos Health®, we look toward the future as we apply novel approaches to oncology drug development and innovative trial design, including cellular and gene therapy clinical trials and investigator-led and cooperative group trials. To provide unparalleled depth of expertise, this group is further specialized in three areas:
With teams focused in each of these areas, as well as dedicated experts for Early Phase Oncology and the Asia-Pacific Region, we are structured to support oncology product development at every scale, from emerging biotechnology organizations to large pharmaceutical companies.
Qu'ils soient motivés par le parcours personnel d'un patient atteint de cancer ou par le défi et la rigueur de la recherche clinique sur le cancer, chez Syneos Health, nous sommes passionnés par la collaboration pour trouver un remède.
Looking to the future in cell and gene therapies
Cell and gene therapy (CGT) clinical trials often involve treatment aspects that are novel to investigators, site staff and patients alike. Unfamiliar aspects of treatment and operations, including complex logistical considerations, need to be executed in a rapidly evolving regulatory landscape.
We bring deep experience managing these challenges to each CGT engagement, supported by the Syneos Health Cell and Gene Therapy Consortium, the hub for our knowledge and experience base in CGT translational science, clinical development, regulatory strategy and commercialization.
Contenu apparenté
Looking for exclusive insight?
